Skip to content

A randomized controlled trial to assess the hepatoprotective effects of dexmedetomidine in pediatric living-donor liver transplantation recipients

A randomized controlled trial to assess the hepatoprotective effects of dexmedetomidine in pediatric living-donor liver transplantation recipients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040680
Enrollment
Unknown
Registered
2020-12-08
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic ischemia reperfusion injury

Interventions

Experimental group:Dexmedetomidine preconditioning during pure laparoscopic donor hepatectomy
Control group:Normal saline preconditioning during pure laparoscopic donor hepatectomy

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 12 Years

Inclusion criteria

Inclusion criteria: 1. Aged younger than 12 years of age; 2. Left lateral lobe grafts procured from living-related donors following pure laparoscopic donor hepatectomy; 3. liver grafts preserved with Celsior solution and implanted using the modified piggy-back technique; 4. Without severe cardiac, pulmonary, kidney and cerebral diseases.

Exclusion criteria

Exclusion criteria: 1. Severe congenital heart diseases accompanied with cardiac?insufficiency or pulmonary hypertension; 2. Stage III or IV encephalopathy; 3. Severe cardiopulmonary disease, such as hepatopulmonary?syndrome (PaO2133 umol/L); 4. Requiring preoperative vasopressor or mechanical ventilation support; 5. Synchronously meet the exclusion criteria of the one-to-one matched donor.

Design outcomes

Primary

MeasureTime frame
postoperative liver transaminases levellevels;the severity of hepatic ischemia-reperfusion injury;

Secondary

MeasureTime frame
Intraoperative hemodynamic parameters;Other postoperative liver function indicators;postoperative kidney function;Intraoperative dosage of vasopressors;Histopathological assessments;Intraoperative serum inflammatory cytokines and oxidative stress indicators;Duration of mechanical ventilation, and intensive care unit and hospital stay;Postoperative complications;

Countries

China

Contacts

Public ContactFu-Shan Xue

Capital Medical University affiliated Beijing Friendship Hospital

xuefushan@aliyun.com+8610 63138362

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026